Objective:

Review the FDA-approved single-port robotic platform’s features, workflow, and implementation considerations across colorectal procedures.

Approach:

• Task force: Colorectal surgeons experienced in laparoscopic and multiport robotic procedures, with initial exposure to single-port platforms, evaluated the FDA-approved platform.
• Evidence and procedures: The task force reviewed published literature, cadaveric studies, and collective expert experience concerning TAMIS, right colectomy, and low anterior resection/total mesorectal excision. Topics included technical steps, patient selection, workflow, and early clinical outcomes.
• Review process: All task force members iteratively reviewed the manuscript for accuracy and clinical applicability.

Key Findings:

• The platform has a 25 mm multichannel cannula containing three working-instrument channels and one camera channel, with three articulating instruments and a flexible 3-D camera; it received specific FDA approval for colorectal surgery in 2024.
• A single robotic arm and 360-degree boom rotation permit access to multiple abdominal quadrants without multiport docking or repositioning.
• The cannula arrangement and articulating instruments are designed to preserve triangulation and address instrument crowding associated with earlier single-incision approaches.
• For transanal procedures, the flexible camera provides views of the rectal walls, while a third robotic arm can provide retraction for full-thickness excision and suture closure.

Interpretation:

The review describes the platform’s design and technical applications in colorectal surgery. Definitive comparative evidence regarding wound morbidity remains limited.

Limitations:

• Definitive comparative evidence on wound morbidity is limited.
• Equivalence to multiport robotic surgery has not been established.

Sources:

• Article context supplied by the user